STOCK TITAN

State Street discloses 5.2% Akebia Therapeutics stake (AKBA)

Filing Impact
(Neutral)
Filing Sentiment
(Neutral)
Form Type
SCHEDULE 13G

Rhea-AI Filing Summary

State Street Corporation has disclosed a passive ownership stake in Akebia Therapeutics Inc. common stock on a Schedule 13G. As of 12/31/2025, State Street reported beneficial ownership of 13,687,561 shares, representing 5.2% of Akebia’s outstanding common stock.

State Street reported no sole voting or dispositive power over these shares, but shared voting power over 13,169,907 shares and shared dispositive power over 13,687,561 shares. The filing states the securities were acquired and are held in the ordinary course of business, not to change or influence control of Akebia.

Positive

  • None.

Negative

  • None.





Check the appropriate box to designate the rule pursuant to which this Schedule is filed:
Rule 13d-1(b)
Rule 13d-1(c)
Rule 13d-1(d)






SCHEDULE 13G





SCHEDULE 13G



STATE STREET CORPORATION
Signature:ELIZABETH SCHAEFER
Name/Title:SENIOR VICE PRESIDENT, CHIEF ACCOUNTING OFFICER
Date:02/09/2026

FAQ

What percentage of Akebia Therapeutics (AKBA) does State Street Corporation own?

State Street Corporation reports beneficial ownership of 5.2% of Akebia Therapeutics’ common stock. This stake equals 13,687,561 shares held with shared voting and dispositive power, as disclosed in a Schedule 13G for the event date 12/31/2025.

How many Akebia Therapeutics (AKBA) shares are beneficially owned by State Street?

State Street Corporation reports beneficial ownership of 13,687,561 Akebia Therapeutics common shares. It has shared voting power over 13,169,907 shares and shared dispositive power over 13,687,561 shares, with no sole voting or dispositive authority reported.

Is State Street’s Akebia Therapeutics (AKBA) stake considered passive or active?

The stake is described as passive. State Street certifies the securities were acquired and are held in the ordinary course of business and not for the purpose of changing or influencing control of Akebia, consistent with a Schedule 13G filing.

What is the event date for State Street’s Schedule 13G on Akebia Therapeutics (AKBA)?

The event date triggering this Schedule 13G is 12/31/2025. As of that date, State Street Corporation reported beneficial ownership of 13,687,561 Akebia common shares, representing 5.2% of the class, with shared voting and dispositive powers.

Which State Street affiliates are involved in the Akebia Therapeutics (AKBA) holdings?

Identified affiliates include SSGA Funds Management, Inc., State Street Global Advisors Europe Limited, State Street Global Advisors Limited, State Street Global Advisors Trust Company, and State Street Global Advisors, Ltd., each referenced as investment adviser entities connected to the reported holdings.

Does State Street have sole voting power over Akebia Therapeutics (AKBA) shares?

State Street reports no sole voting power over Akebia shares. The filing shows shared voting power for 13,169,907 shares and shared dispositive power for 13,687,561 shares, reflecting that authority is held collectively rather than solely.
Akebia Therapeut

NASDAQ:AKBA

AKBA Rankings

AKBA Latest News

AKBA Latest SEC Filings

AKBA Stock Data

368.86M
250.09M
3.56%
43.24%
10.22%
Drug Manufacturers - Specialty & Generic
Pharmaceutical Preparations
Link
United States
CAMBRIDGE